Neuronetics grants cash and RSU awards to executives

Neuronetics, Inc. reported that its Compensation Committee approved new cash and restricted stock unit awards for two senior executives.

Rhea-AI Filing Summary

Neuronetics, Inc. reported that its Compensation Committee approved new cash and restricted stock unit awards for two senior executives. Steven E. Pfanstiel, Executive Vice President, Chief Financial Officer and Treasurer, received a cash award of $240,000 and 170,212 restricted stock units. W. Andrew Macan, Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, received a cash award of $231,750 and 164,361 restricted stock units. The cash awards will be paid and the RSUs will vest on the earlier of June 30, 2027 or a termination of employment without cause.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive compensation changes did Neuronetics (STIM) disclose in this 8-K?

Neuronetics disclosed that its Compensation Committee approved cash and restricted stock unit awards for two executives, Steven E. Pfanstiel and W. Andrew Macan.

How much cash did Neuronetics (STIM) award to its executives?

Steven E. Pfanstiel received a $240,000 cash award, and W. Andrew Macan received a $231,750 cash award.

How many RSUs were granted to Neuronetics executives Steven Pfanstiel and Andrew Macan?

Steven E. Pfanstiel was granted 170,212 restricted stock units, and W. Andrew Macan was granted 164,361 restricted stock units.

When do the new RSU awards for Neuronetics (STIM) executives vest?

The RSUs vest on the earlier of June 30, 2027 and a termination of employment without cause.

When will the cash awards to Neuronetics executives be paid?

The cash awards will be paid on the earlier of June 30, 2027 and a termination of employment without cause.

Which Neuronetics executive signed this 8-K report?

The report was signed on behalf of Neuronetics, Inc. by W. Andrew Macan, Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 05:00 PM EST Learn about SEC filing dates

false 0001227636 0001227636 2025-12-30 2025-12-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 30, 2025

NEURONETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38546		33-1051425
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3222 Phoenixville Pike, Malvern, PA		19355
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 600-7555

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		STIM		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On December 30, 2025, the Compensation Committee of the Board of Directors of Neuronetics, Inc. (the “Company”) approved cash awards and restricted stock unit incentive compensation awards (“RSUs”) for Steven E. Pfanstiel, the Company’s Executive Vice President, Chief Financial Officer and Treasurer, and W. Andrew Macan, the Company’s Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, in the amounts of $240,000 and $231,750, respectively, and 170,212 and 164,361 RSUs, respectively. The cash awards will be paid and the RSUs vest on the earlier of June 30, 2027 and a termination of employment without cause.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				NEURONETICS, INC.
Date: January 6, 2026				By:		/s/ W. Andrew Macan
				Name:		W. Andrew Macan
				Title:		EVP, General Counsel, Chief Compliance Officer and Corporate Secretary